Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Pulls U.K. Ads Comparing Zyvox To Vancomycin

This article was originally published in The Pink Sheet Daily

Executive Summary

U.K.' s MHRA asked Pfizer to withdraw advertising for the antibiotic.

You may also be interested in...



FDA Alert Advises Of Emerging Safety Concerns With Pfizer’s Zyvox

Patients treated with the antibiotic for catheter site infections had a higher incidence of death compared to patients treated with comparators.

FDA Alert Advises Of Emerging Safety Concerns With Pfizer’s Zyvox

Patients treated with the antibiotic for catheter site infections had a higher incidence of death compared to patients treated with comparators.

FDA Warning Letter For Pfizer Zyvox Promotion Charges Implied Superiority

A professional journal advertisement describes a higher cure rate for linezolid than for vancomycin in methicillin-resistant Staphylococcus aureus, a claim not supported by evidence, the agency says.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS065862

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel